Is Sonnet Biotherapeutics Holdings Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: SONN) stock is to Strong Buy SONN stock.
Out of 2 analysts, 2 (100%) are recommending SONN as a Strong Buy, 0 (0%) are recommending SONN as a Buy, 0 (0%) are recommending SONN as a Hold, 0 (0%) are recommending SONN as a Sell, and 0 (0%) are recommending SONN as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year SONN price target, the average SONN price target is $18.50, with the highest SONN stock price forecast at $30.00 and the lowest SONN stock price forecast at $7.00.
On average, Wall Street analysts predict that Sonnet Biotherapeutics Holdings's share price could reach $18.50 by Feb 15, 2025. The average Sonnet Biotherapeutics Holdings stock price prediction forecasts a potential upside of 945.2% from the current SONN share price of $1.77.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.